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Outline 
• Short stature 
• Abnormal Puberty 
– Precocious Puberty 
– Delayed Puberty 
• Diabetes 
– Type 1 Diabetes 
– Type 2 Diabetes 
 
Short Stature 
Definitions 
• Short Stature: height more than 2 standard 
deviations below mean for age 
– <3rd percentile 
• Mid parental height 
– Girls [(Father’s ht – 5in)+ Mother’s ht]/2 
– Boys [(Mother’s ht + 5in)+ Father’s ht]/2 
• Target height 
– MPH +/- 2 SD (1 SD = 2 inches) 
Normal Growth 
• Normal growth rate is age and pubertal 
status specific 
• Age 
– 0-6 months : 1 inch per month 
– 7-12 months: ½ inch per month 
– 12-24 months: >4 inches per year 
– 24-36 months: 3 inches per year 
– 36-48 months: 2.75 cm per year 
– 4-10 years: 2-2.4 inches per year 
Growth Measurement 
Measure 3 times (should have <0.3 cm variation) 
and take mean 
• Age <2 years 
– Supine length 
– Firm board with fixed head plate and moveable foot 
plate 
• Age >2 years 
– Wall mounted stadiometer 
– No shoes, hair down 
– Head, thoracic spine, buttocks and heels should be 
touching the vertical surface 
Growth Measurement Cont… 
• Growth velocity provides the earliest 
identification of problems with growth 
• Growth velocity is best assessed using 
measurements taken at 3- to 4-monthly intervals 
in infants and at 6-monthly intervals in older 
children 
• An appropriate growth chart is an essential tool 
for the screening, surveillance and monitoring of 
children's growth. 
 
Red Flags 
Abnormal growth velocity  
Crossing percentile curves (after 18 months) 
Height below 3rd percentile 
Significantly short for family 
Weight loss 
Excessive weight gain 
A) Proportionate Short Stature 
         1) Normal Variants: 
                    i) Familial 
                    ii) Constitutional Growth Delay 
         2) Prenatal Causes: 
                    i) Intra-uterine Growth Restriction- 
                            Placental causes, Maternal nutrition, 
      Teratogens 
                    ii) Intra-uterine Infections 
                    iii) Genetic Disorders (Chromosomal   
                             & Metabolic Disorders)  
Causes Of Short Stature 
     3) Postnatal Causes: 
               i) Undernutrition 
               ii) Chronic Systemic Illness 
                    - Cardiopulmonary: CHD, Chronic  
     Asthma, Cystic Fibrosis 
                    - Renal: RTA, CRF, Steroid     
     dependent  Nephrotic Syndrome 
                    - GI and Hepatic: Malabsorption,   
     IBD, chronic liver disease 
                    - Chronic Severe Infections 
                    - Hematological : Thalassemia,   
     Sickle cell disease, anemia               
Causes of Short Stature Cont… 
iii) Psychosocial Short Stature 
         (emotional deprivation)         
 
iv) Endocrine Causes: 
              - Growth Hormone Deficiency/  
    insensitivity 
              - Hypothyroidism 
              - Juvenile Diabetes Mellitus 
              - Cushing Syndrome 
              - Pseudohypoparathyroidism 
              - Precocious/ delayed puberty       
 
Causes of Short Stature Cont… 
 B) Disproportionate Short Stature 
          1) With Short Limbs: 
                 - Achondroplasia, Hypochondroplasia,  
                    Chondrodysplasia punctata,  
                    Chondroectodermal Dysplasia, 
                    Diastrophic dysplasia, Metaphyseal 
                    Chondrodysplasia 
                 - Deformities due to Osteogenesis   
     Imperfecta, Refractory Rickets 
 
         2) With Short Trunk: 
                 - Spondyloepiphyseal dysplasia, 
                   Mucolipidosis, Mucopolysaccharidosis 
                 - Caries Spine, Hemivertebrae       
Causes of Short Stature Cont… 
Work Up 
• Thorough history including personal and family 
health history, pubertal history 
• Review of Growth Chart 
• Exam, including height and proportion 
measurements 
• Initial: CBC, UA, Electrolytes, T4/TSH, ESR 
• Bone Age 
• Specialized: IGF-1, IGFBP3, Karyotype (girls), 
stool studies, ? Sweat Chloride test 
Familial Short Stature 
• Attain the 
appropriate % 
• Normal linear 
growth, parallel to 
the curve 
Constitutional Delay 
• Growth slows in 
1st 2 years 
• Skeletal 
maturation, 
puberty delayed 
• Final height 
appropriate 
Endo Causes 
• Abnormal 
growth 
velocity 
• Failure to 
maintain 
height % 
 
 
IGF and IGFBP 
• GH (anterior pituitary) 
– Pulsatile 
– Regulated by GHRH  and 
somatostatin  
• IGF-1 – stimulated by 
GH  
• IGF-BP – correlated with 
GH secretion 
Growth Hormone 
• FDA indications: 
– Growth Hormone Deficiency 
(1985) 
– Chronic Renal Failure (1993) 
– Turner Syndrome (1997) 
– Prader-Willi Syndrome (2000) 
– Small for gestational age (2001) 
– Idiopathic Short Stature (2003) 
– SHOX gene deficiency (2006) 
– Noonan syndrome (2007) 
 
Effect of Growth Hormone 
• GH dose of 0.15 – 0.3 mg/kg/week 
– SQ, 6-7 once daily doses 
• Side effects (uncommon) –Pseudotumor cerebri, 
SCFE 
• In GH deficiency: Treatment outcome depends on 
duration and dose 
– First year : 9-10 cm  
– Next 2 years 5-6 cm/year 
• In ISS: Overall height gain of 3.5-7.5 cm 
 
Puberty 
Puberty 
Definitions 
• Puberty: developmental stage child   young adult 
– maturation of gametogenesis 
– secretion of gonadal hormones 
– secondary sexual characteristics 
– reproductive functions.  
• Thelarche: onset of breast development, an estrogen effect.  
• Pubarche:  onset of sexual hair growth, an androgen effect 
• Menarche: onset of menses 
• Spermarche: appearance of spermatozoa in seminal fluid.  
• Adrenarche: refers to the onset of the adrenal androgen 
production that contributes to pubarche. 
Onset of Puberty 
• #1 determinant: genetics, ethnicity 
• Other factors: hormonally active environmental 
chemicals, nutrition,  general health 
 
Girls: Breast buds 8-13 y Boys: Testicular enlargement 9-14y 
SMR Girls 
menses Growth spurt 
SMR Boys 
Enlargement 
of scrotum 
and testis 
Adult 
Genitalia 
Growth spurt 
Enlargement 
of penis in 
length 
Development 
of Glans, 
enlargement of 
penis width 
Prepubertal 
 Signs of puberty 
before the age of 8y 
  
  
Signs of puberty 
before the age of 9y 
Abnormal Puberty 
 No breast 
development by 
the age of 13y 
 No menarche at 
15y  primary 
amenorrhea 
  
  
OR 
No testicular 
enlargement 
by the age of 
14y 
OR 
Questions for PCP 
• History and Exam (tanner stage - SMR) 
 
– Is pubertal development really occurring outside the 
normal temporal range?  
 
– What is the underlying mechanism, is it associated 
with a risk of a serious condition? 
 
– If puberty progresses, would this impair the child’s 
normal physical and psychosocial development? 
 
Concern for Precocious puberty 
Normal  
Age > 8 years 
Progression 
over 2-5 y 
Familial 
Ethnicity 
Premature 
Adrenarche  
NO breasts or Testes 
Elevated Adrenal 
Androgens 
Idiopathic Benign 
Premature Adrenarche 
(#1), Late Onset CAH, 
Androgen secreting tumors 
“True”  Precocious Puberty      
BREASTS or TESTES 
Central 
(gonadotropin)  
High LH and FSH 
(stim test)    
Advanced BA 
Idiopathic (#1),    
CNS lesions 
Peripheral  
Normal LH and 
FSH, High  E or T. 
Advanced BA 
Tumors (ovarian, 
testicular, adrenal). 
MCCunne 
Albrights. 
Testotoxicosis. 
Exposures 
Minipuberty 
of Infancy 
Etiologies 
Evaluation 
• PHYSICAL EXAM 
– Growth chart 
• Growth velocity 
– Tanner Staging 
– Skin 
• Birth marks 
• Acne, facial hair 
• Acanthosis, 
striae 
– Neuro exam – 
cranial nerves 
• HISTORY 
– Age of onset 
– First sign/symptom 
– Other signs/symptoms 
• Breast/testes 
• Vaginal discharge 
• Erections 
• Acne,  Facial hair, 
Body odor 
• Growth spurt 
• CNS symptoms 
– Rate of Progression 
– Past medical history 
– Family History 
• Age of menarche, 
end of growth spurt, 
Mid parental height 
 
• WORK-UP 
– Hormone 
measurements 
• Gonadotropins: 
LH, FSH 
• Gonads: 
Estradiol, 
Testosterone 
• Adrenals: 17 
OHP, DHEA-S, 
Androstenedione 
• Metabolic 
Syndrome (?) 
– Bone Age 
– Other (?) 
• Brain MRI 
• Pelvic US 
• Testicular US 
Treatment :CPP 
• CPP: GnRH agonist administration results in an 
initial transient stimulation of gonadotropin 
secretion from the pituitary, followed by a 
complete, but reversible, suppression of the 
pituitary-gonadal axis 
– Depot Lupron 7.5 mg every 28 days or 11.25 mg 
every 28 days or 15 mg every 28 days 
– Depot Lupron 11.25 mg every 3 months or 30 mg 
every 3 months 
– Histrelin Implant upto 1 year 
Treatment : Peripheral Puberty 
• Peripheral Precocious Puberty: Does not respond to 
GnRH agonist therapy. Instead, treatment is directed at 
removing or blocking the production of and/or response 
to the excess sex steroids, depending on the cause:  
– Tumors of the testis, adrenal gland, or ovary – These are treated 
by surgery. hCG-secreting tumors may also require radiation 
therapy and chemotherapy, depending upon the site and 
histologic type. 
– Functioning follicular cysts of the ovary – These develop and 
regress spontaneously, so conservative management without 
surgery is generally appropriate  
– Exposure to exogenous sex steroids – The source should be 
identified and removed. After removal, the pubertal changes are 
likely to regress.  
Concerns for Delayed puberty 
Constitutional 
+ Family history. 
Variant of 
normal? 
 Gonadotropin 
Deficiency 
LOW LH and FSH 
CNS 
Lesions 
Chronic 
Illness 
Low BMI 
Kallmann 
Gonadal Failure 
HIGH LH and FSH 
Turner 
Klinefelter 
 DSD’s 
Radiation 
ChemoTx 
Autoimmune  
surgical 
Etiology: Delayed Puberty 
Evaluation 
• PHYSICAL EXAM 
– Growth chart 
• Growth 
velocity 
• BMI 
– Tanner Staging 
– GU exam 
– Neuro exam – 
cranial nerves 
• HISTORY 
– Age of evaluation 
– Signs present/absent 
• Breast/testicular 
changes 
• Vaginal 
discharge/bleeding 
• Erections 
• Growth spurt 
• CNS symptoms 
• Anosmia 
• Diet and Exercise 
– Past medical history 
– Family History 
• Age of menarche, 
end of growth spurt 
• Mid parental height 
 
• WORK-UP 
– Labs 
• Gonadotropins: 
LH, FSH 
• Gonads: 
Estradiol, 
Testosterone 
• Pituitary: growth 
factors, thyroid, 
prolactin (F) 
• Chronic illness 
– Bone Age 
– Other (?) 
• Brain MRI 
• Pelvic US 
• Testicular US 
Constitutional Delay 
• "Watchful waiting" with reassurance and 
psychological support for the patient and family.  
• Administration of gonadal steroids 
• Short-term therapeutic goals include: 
– Attainment of age-appropriate secondary sex 
characteristics  
– Induction of a growth spurt without inducing 
premature epiphyseal closure 
– Potential induction of puberty 
 
 
Treatment: Delayed Puberty 
Diabetes 
Diabetes 
ADA Diagnostic Criteria 
1. HbA1C ≥6.5%*.  
                                                 OR 
2. FPG ≥126 mg/dl (7.0 mmol/l). Fasting is defined as no 
caloric intake for at least 8 h.  
                                                 OR 
3. 2-h plasma glucose ≥200 mg/dl (11.1 mmol/l) during 
a 75 g OGTT.   
                                                  OR 
4. In a patient with classic symptoms of hyperglycemia 
or hyperglycemic crisis, a random plasma glucose 
≥200 mg/dl (11.1 mmol/l). 
Epidemiology 
How prevalent is type 2 diabetes in children? 
A. 1 in 100 
B. 1 in 500 
C. 1 in 1,000 
D. 2 in 10,000 
Correct answer: D 
Although there are no good epidemiologic studies on type 
2 diabetes, data from SEARCH (a clinic-based 
observational study) suggest that the prevalence of 
diagnosed type 2 diabetes is about 2 per 10,000 children.  
 
 
Epidemiology of Diabetes 
• T1D is the most common form of diabetes in 
children (80% of all pediatric diabetes)  
– 1 in 300-500 
 
• T2D Ethnicity- and race-specific prevalence are:   
– Non-Hispanic whites: 1.9 per 10,000 
– Hispanics: 4.8 per 10,000 
– Asian Americans: 5.4 per 10,000 
– African Americans: 10.5 per 10,000 
 SEARCH for Diabetes in Youth Study Group. Liese AD, D'Agostino RB Jr, Hamman RF, et al. The burden of diabetes mellitus among US 
youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics. 2006;118(4):1510–1518.  
• Incidence in the US 
– 27 new cases per year per 100,000 population 
– Increasing since the 1960’s 
 
• Age at diagnosis  
– From 6 months to adulthood 
– Incidence peaks at age 12 (10-14) years 
 
• Race/ethnicity  
– All races/ethnicities but most common in non-Hispanic Whites 
 
Epidemiology of T1D 
Eisenbarth Model of Stages in 
T1D Development 
Modified from G.S. Eisenbarth NEJM 1986 
DIABETES 
Type 1 and 2 Diabetes Differentiation 
• Type 1 diabetes:  
– absolute deficiency of insulin (often 
autoimmune) 
 
• Type 2 diabetes:  
– insulin resistance with a relative insulin 
deficiency 
 
 
Type 1 Type 2 
Ethnicity/race 
European-
Americans 
Native Americans 
Hispanics 
African Americans 
Asians 
Family history of diabetes mellitus Rare >80% 
Polycystic ovarian syndrome Rare Common 
Acanthosis nigricans Not seen Common 
Overweight Less common 100% 
Diabetic ketoacidosis at diagnosis >50% <<50% 
C-peptide (associated with insulin 
production) or insulin 
Low or undetectable High or normal 
Antibodies associated with type 1 
diabetes: GAD 65, IA2 
 Usually positive Usually negative 
Type 1 and 2 Diabetes Differentiation 
• In otherwise ‘typical’ T2D, diabetes autoantibody 
testing should be considered because of high 
frequency of islet cell autoimmunity 
– Pre-pubertal children are unlikely to have T2D even if 
obese 
– +Antibodies with high C-peptide  
• support the diagnosis of T1D caught before insulin absolute 
insulin deficiency OR 
• “Type 2 DM” who will require insulin for glucose control more 
quickly 
Symptoms and Signs 
Symptoms: 
• 3 Polys: 
• Increased thirst* 
• Increased urination* 
• Increased appetite 
• Weight loss 
• Nausea  
• Vomiting 
• Abdominal pain* 
• Rapid breathing* 
• Fatigue 
• Dehydration* 
• Altered mental status 
 
 
*Denotes signs and symptoms in DKA  
Signs: 
• Increased HR* 
• Decreased BP 
• Tachypnea* 
• Dry mucous membranes* 
• Delayed capillary refill* 
• Change in weight %’s 
• Fruity odor to breath* 
• Abdominal tenderness* 
• Obtundation 
• Coma 
 
 
Diabetic Ketoacidosis 
D – Diabetes (extreme hyperglycemia : Plasma 
Glucose>250 mg/dl) 
K – Ketones (urine vs. serum) 
A – Acidosis  (pH <7.3, HCO3 <15) 
Cerebral edema - most common fatal complication of DKA 
 Risk Factors: young age, new diagnosis, severity of acidosis, 
increase BUN at presentation, use of bicarb for tx 
 Neurologic deterioration  Give IV Mannitol 1g/kg  (don’t wait for 
imaging) 
 
Management T1D 
• Family Education 
• Glucose monitoring 
• Nutrition/Carbohydrate counting 
• Insulin 
• Monitoring for complications and comorbidities 
 
T1 D Management: Goals 
GOAL: mimic the function of the pancreas with basal and 
bolus insulin 
• Basal: insulin required during fasting in order to 
cover glucose released by liver  
• Bolus: insulin required to cover carbohydrates or 
to correct a high blood glucose 
– Carb Ratio, Correction Factor 
 
• Ideal pediatric blood sugar range: 80-180 mg/dl 
• HbA1c goal as defined by ADA: <7.5% 
T1D Management : Insulin Types 
• Rapid acting insulin analogs 
–Lispro, Aspart, Glulisine 
• Short acting 
–Regular 
• Intermediate acting 
–NPH 
• Long acting / Basal  
–Detemir, Glargine, Basaglar, Tresiba 
Faster 
Acting 
Longer 
Lasting 
Basal/bolus: 4 shot regimen 
         Rapid Insulin 
 
         Glargine Insulin 
- Extra injection 
- Flexibility with meals 
- Improved glycemic control 
- Weight gain? 
Insulin Pumps: Open Loop 
• What do they do? 
• Basal rate(s) 
• Food boluses 
• Correction bolus 
 
• What don't they do? 
• User must enter BGs, carbs, etc. 
Insulin Pumps: Closing the Loop 
MiniMed670G: The First Hybrid Closed Loop 
System (FDA approved Sept 2016) 
 
The Medtronic MiniMed 670G system is intended for continuous 
delivery of basal insulin (at user selectable rates) and 
administration of insulin boluses (in user selectable amounts) for 
the management of Type 1 diabetes mellitus in persons, fourteen 
years of age and older, requiring insulin as well as for the 
continuous monitoring and trending of glucose levels in the fluid 
under the skin. The MiniMed 670G System includes SmartGuard 
HCL technology, which can be programmed to automatically 
adjust delivery of basal insulin based on Continuous Glucose 
Monitor sensor glucose values, and can suspend delivery of 
insulin when the sensor glucose value falls below or is predicted 
to fall below predefined threshold values. 
Management T2D 
• Family education 
• Glucose monitoring 
• Lifestyle modifications 
– Nutrition 
– Physical activity 
• Pharmacotherapy 
• Treatment of comorbidities and complications 
Management T2D: Education 
• Families of children with type 2 diabetes should 
be informed that some risk factors for diabetes 
are not modifiable (e.g., genetics), while others 
are modifiable (e.g., weight) 
• They should also understand that physical 
activity and weight loss can help normalize 
glucose concentrations by reducing insulin 
resistance 
Management: Glucose Goal 
• Goal is to achieve an A1c < than 7% 
– Equivalent to fasting glucose concentration of 70-130 
mg/dL and post prandial glucose concentration <180 
mg/dl 
 
Ways to lower glucose in T2D 
• Decreasing insulin resistance 
– Physical Activity 
– Weight loss 
– Use of certain medicines (insulin sensitizers) 
• Increasing insulin secretion 
– Drugs (not FDA approved in children)  
– Insulin 
Metformin 
• First-line treatment for T2D in children 
 
• Dosing: 
– Start with a low dose (500 mg) and increasing the dose by 
500 mg every 3 to 7 days. The maximum effective dose is 
2,000 mg/day 
– Example: 
• Week 1: 500 mg PO with dinner 
• Week 2: 500 mg PO with breakfast and 500 mg PO with dinner 
• Week 3: 500 mg PO with breakfast and 1000 mg PO with dinner 
• Week 4: 1000 mg PO with breakfast and 1000 mg PO with dinner 
 
• Does not cause weight gain or hypoglycemia 
Thank you for your time 
and attention!!! 
Questions? 
